EHA 2022 | Pathobiology & treatment of T-PLL
Marco Herling
• 12 Jun 2022
Marco Herling, MD, University of Leipzig, Leipzig, Germany, comments on the pathobiology of T-cell prolymphocytic leukemia (T-PLL), discussing current and future management strategies for this condition. T-PLL is characterized by an aberrant DNA damage response, rendering this disease resistant to many single-agent therapies, including the current frontline standard of care (SOC) alemtuzumab. Dr Herling emphasizes the importance of targeting this disease with several drugs and mentions a recent study evaluating the combination of itacitinib and alemtuzumab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
